X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
proviruses - genetics (590) 590
humans (542) 542
animals (483) 483
virology (326) 326
molecular sequence data (265) 265
index medicus (257) 257
base sequence (250) 250
viruses (249) 249
mice (236) 236
proviruses (225) 225
hiv-1 - genetics (187) 187
cell line (176) 176
dna (164) 164
female (159) 159
dna, viral - genetics (150) 150
expression (143) 143
cells, cultured (140) 140
hiv (137) 137
polymerase chain reaction (137) 137
research article (136) 136
virus replication (136) 136
research (133) 133
male (130) 130
gene expression (121) 121
proviruses - isolation & purification (121) 121
dna, viral - analysis (110) 110
virus integration (110) 110
multidisciplinary sciences (109) 109
hiv-1 - growth & development (106) 106
lymphocytes (106) 106
proviruses - physiology (103) 103
infection (102) 102
biochemistry & molecular biology (101) 101
transfection (101) 101
immunology (100) 100
proviruses - growth & development (100) 100
retroviridae - genetics (100) 100
transcription, genetic (99) 99
amino acid sequence (95) 95
replication (94) 94
cell biology (93) 93
cloning, molecular (93) 93
genomes (93) 93
genetic aspects (90) 90
mutation (89) 89
long terminal repeat (88) 88
microbiology (86) 86
health aspects (85) 85
virus diseases (83) 83
infectious diseases (82) 82
rna (82) 82
hiv-1 - physiology (81) 81
human-immunodeficiency-virus (81) 81
gene expression regulation, viral (80) 80
infections (80) 80
genetic vectors (78) 78
hiv infections - virology (77) 77
human immunodeficiency virus--hiv (77) 77
adult (74) 74
viral load (74) 74
genetics & heredity (73) 73
proteins (73) 73
cells (70) 70
genes (70) 70
hiv-1 (70) 70
gene (69) 69
protein (69) 69
analysis (67) 67
aids (66) 66
middle aged (66) 66
oncology (66) 66
genes, viral (63) 63
in-vivo (61) 61
rna, viral - genetics (61) 61
physiological aspects (60) 60
medicine, research & experimental (59) 59
human t-lymphotropic virus 1 - genetics (57) 57
murine leukemia-virus (57) 57
retrovirus (57) 57
t cells (56) 56
hiv infection (55) 55
genome, viral (54) 54
cell lines (52) 52
deoxyribonucleic acid--dna (52) 52
biotechnology & applied microbiology (51) 51
identification (51) 51
leukemia (51) 51
transcription (51) 51
activation (50) 50
genomics (50) 50
type-1 (50) 50
hematology (49) 49
restriction mapping (49) 49
blotting, southern (48) 48
plasmids (48) 48
tumor cells, cultured (48) 48
article (47) 47
biology (46) 46
gene-expression (46) 46
hiv-1 - drug effects (46) 46
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Human Cell, ISSN 0914-7470, 4/2019, Volume 32, Issue 2, pp. 185 - 192
We previously reported the diversity of structure and integration sites of human T-cell leukemia virus type 1 (HTLV-1) provirus among different MT-2 cell... 
Life Sciences | Stem Cells | Cytokine production | Tumor necrosis factor | Surgery | Gynecology | Oncology | HTLV-1 | Reproductive Medicine | Cell Biology | MT-2 cell lines | Interferon gamma | ACTIVATION | PROLIFERATION | CELL BIOLOGY | INTERFERON-GAMMA | LEUKEMIA | EXPRESSION | HUMAN CORD LEUKOCYTES | ANTIGEN
Journal Article
Nature, ISSN 0028-0836, 07/2012, Volume 487, Issue 7408, pp. 482 - 485
Despite antiretroviral therapy, proviral latency of human immunodeficiency virus type 1 (HIV-1) remains a principal obstacle to curing the infection(1).... 
CELLS | ACTIVATION | SUBEROYLANILIDE HYDROXAMIC ACID | MULTIDISCIPLINARY SCIENCES | IN-VIVO | VALPROIC ACID | INFECTION | HISTONE DEACETYLASE INHIBITORS | TYPE-1 | EXPRESSION | PCR | Gene Expression Regulation, Viral - drug effects | Humans | Hydroxamic Acids - adverse effects | Histone Deacetylase Inhibitors - administration & dosage | RNA, Viral - blood | Virus Latency - drug effects | Proviruses - drug effects | HIV-1 - growth & development | Proviruses - genetics | Hydroxamic Acids - administration & dosage | Anti-HIV Agents - therapeutic use | CD4-Positive T-Lymphocytes - virology | Hydroxamic Acids - pharmacology | Biomarkers - metabolism | HIV Infections - blood | Risk Assessment | HIV-1 - drug effects | CD4-Positive T-Lymphocytes - cytology | HIV Infections - virology | RNA, Viral - biosynthesis | CD4-Positive T-Lymphocytes - metabolism | Viremia - drug therapy | HIV-1 - genetics | Proviruses - growth & development | Histones - drug effects | Up-Regulation - drug effects | Acetylation - drug effects | Viremia - virology | HIV Infections - drug therapy | Histone Deacetylase Inhibitors - pharmacology | Histones - metabolism | CD4-Positive T-Lymphocytes - drug effects | Histone Deacetylase Inhibitors - adverse effects | Physiological aspects | Antiviral agents | HIV patients | Health aspects | Vorinostat | Antiretroviral drugs | Plasma | Cell culture | Lymphocytes | Human immunodeficiency virus--HIV | Genomes | Drug therapy | Drug dosages
Journal Article
Nature, ISSN 0028-0836, 07/2016, Volume 535, Issue 7613, pp. 556 - 560
Interruption of combination antiretroviral therapy in HIV-1-infected individuals leads to rapid viral rebound. Here we report the results of a phase IIa open... 
POTENT | REPLICATION | GENETIC-DETERMINANTS | BROADLY NEUTRALIZING ANTIBODIES | MULTIDISCIPLINARY SCIENCES | PASSIVE TRANSFER | SEQUENCE | CD4 BINDING | ANTIRETROVIRAL THERAPY | INFECTION | MONOCLONAL-ANTIBODIES | Anti-HIV Agents - pharmacology | Antibodies, Neutralizing - administration & dosage | Disease Reservoirs - virology | Humans | Middle Aged | Male | Proviruses - immunology | Anti-HIV Agents - administration & dosage | Tissue Distribution | Young Adult | HIV Infections - immunology | Proviruses - drug effects | Antibodies, Neutralizing - immunology | HIV-1 - growth & development | HIV Antibodies - immunology | HIV Envelope Protein gp160 - chemistry | Time Factors | Antibodies, Neutralizing - therapeutic use | Binding Sites - immunology | Adult | Anti-HIV Agents - therapeutic use | Female | HIV Antibodies - therapeutic use | Historically Controlled Study | Binding Sites - drug effects | HIV Envelope Protein gp160 - metabolism | Drug Administration Schedule | HIV-1 - drug effects | HIV Infections - virology | HIV Antibodies - administration & dosage | Viral Load - immunology | Proviruses - growth & development | HIV-1 - immunology | HIV Envelope Protein gp160 - antagonists & inhibitors | Adolescent | HIV Infections - drug therapy | Aged | HIV Envelope Protein gp160 - immunology | Viral Load - drug effects | CD4 Antigens - metabolism | Prevention | Antiviral agents | HIV antibodies | Dosage and administration | Host-virus relationships | Drug therapy, Combination | Drug therapy | Health aspects | HIV infection | Methods | Clinical trials | Antiretroviral drugs | Immunoglobulins | Human immunodeficiency virus--HIV | Binding sites
Journal Article
Nature, ISSN 0028-0836, 03/2017, Volume 543, Issue 7646, pp. 564 - 567
Journal Article
PLoS Pathogens, ISSN 1553-7366, 02/2013, Volume 9, Issue 2, p. e1003174
HIV-1 reservoirs preclude virus eradication in patients receiving highly active antiretroviral therapy (HAART). The best characterized reservoir is a small,... 
LOW-LEVEL VIREMIA | PLASMA VIREMIA | CD4(+) T-CELLS | MICROBIOLOGY | PERIPHERAL-BLOOD | BLOOD MONONUCLEAR-CELLS | LATENT HIV-1 | INFECTED INDIVIDUALS | VIROLOGY | ACTIVE ANTIRETROVIRAL THERAPY | IN-VIVO | IMMUNODEFICIENCY-VIRUS TYPE-1 | PARASITOLOGY | Proviruses - isolation & purification | Disease Reservoirs - virology | Humans | Middle Aged | DNA, Viral - analysis | Male | Leukocytes, Mononuclear - virology | RNA, Viral - genetics | Proviruses - genetics | Virus Integration - drug effects | Polymerase Chain Reaction | Adult | Female | DNA, Viral - drug effects | Leukocytes, Mononuclear - drug effects | HIV Infections - genetics | HIV Infections - virology | RNA, Viral - analysis | HIV - isolation & purification | Proviruses - growth & development | HIV - growth & development | Antiretroviral Therapy, Highly Active | HIV - genetics | HIV Infections - drug therapy | Aged | DNA, Viral - genetics | RNA, Viral - drug effects | Viral Load - drug effects | Longitudinal Studies | CD4-Positive T-Lymphocytes - drug effects | Physiological aspects | HIV patients | Virulence (Microbiology) | Research | T cells | Health aspects | Plasma | Clinical trials | Statistical methods | Infections | Genomes | Grants | Experiments | Acquired immune deficiency syndrome--AIDS | Lymphocytes | Normal distribution | Human immunodeficiency virus--HIV | Drug therapy | Deoxyribonucleic acid--DNA | AIDS | HIV | Acquired immune deficiency syndrome | Deoxyribonucleic acid | DNA | Human immunodeficiency virus
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 5/2014, Volume 111, Issue 19, pp. 7078 - 7083
Journal Article
Nature, ISSN 0028-0836, 2014, Volume 512, Issue 1, pp. 74 - 77
The viral reservoir represents a critical challenge for human immunodeficiency virus type 1 (HIV-1) eradication strategies(1-5). However, it remains unclear... 
LATENT INFECTION | REPLICATION | INITIATION | MULTIDISCIPLINARY SCIENCES | ACTIVE ANTIRETROVIRAL THERAPY | VACCINE | PREVENTION | DYNAMICS | IMMUNODEFICIENCY VIRUS-INFECTION | DEPENDS | HIV-1 INFECTION | DNA, Viral - biosynthesis | Macaca mulatta - immunology | Simian Immunodeficiency Virus - growth & development | DNA, Viral - analysis | Male | RNA, Viral - blood | Rectum - virology | Macaca mulatta - virology | Simian Acquired Immunodeficiency Syndrome - virology | Proviruses - genetics | Time Factors | Treatment Failure | Female | Disease Models, Animal | Simian Immunodeficiency Virus - immunology | Virus Replication - drug effects | Anti-Retroviral Agents - therapeutic use | Anti-Retroviral Agents - pharmacology | Viremia - drug therapy | Simian Immunodeficiency Virus - physiology | DNA, Viral - blood | Carrier State - virology | Animals | Simian Acquired Immunodeficiency Syndrome - drug therapy | Simian Acquired Immunodeficiency Syndrome - immunology | Viremia - virology | Anti-Retroviral Agents - administration & dosage | Carrier State - drug therapy | Kinetics | Viral Load - drug effects | Simian Immunodeficiency Virus - drug effects | Physiological aspects | Simian immunodeficiency virus | Virulence (Microbiology) | Studies | Antiretroviral drugs | Lymphocytes | Human immunodeficiency virus--HIV | Infections | Monkeys & apes | Deoxyribonucleic acid--DNA
Journal Article